AIM ImmunoTech Inc. AIM shares moved higher on Wednesday after the company secured full approval for a key cancer-related ...

AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancerOCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM ...

AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the Japan Patent Office has fully approved a Japanese patent covering ...

AIM ImmunoTech (AIM) stock jumped 97% after Japan's Patent Office approved its Ampligen cancer treatment patent covering ...

"Prevention and early detection remain some of the most powerful tools we have to reduce cancer risk in the future." ...

Pancreatic cancer is one of the most dangerous and difficult cancers to treat. Doctors often struggle to detect it early ...

A birthing room at the hospital has been named in her honour and now her sister is taking on a fundraising challenge ...

Pancreatic cancer is widely known as one of the most dangerous and difficult cancers to treat. Among the different types of ...

A triple drug approach that blocks the KRAS pathway at three points eliminated pancreatic tumors and prevented resistance in ...

Alisa Clever, 37-year-old wife and mom of two is fighting for her life and needs support. A Bingo and Basket Raffle ...

For the first time in 30 years, there is a new FDA-approved treatment for locally advanced pancreatic cancer. Frederick Health is the first in the U.S. to bring this advancement to patients. It’s ...

Financial firm Mizuho raised its share price target for Tango Therapeutics Inc. (NASDAQ:TNGX) on March 11th. It slightly ...